New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
13:26 EDTAVEOAveo presents results from Phase 1 study of AV-203
AVEO Oncology announced the presentation of results from a first-in-human Phase 1 study of AV-203, AVEO’s ErbB3, HER3, inhibitory antibody candidate. Among the results, the study established a recommended Phase 2 dose of AV-203, demonstrated good tolerability and promising early signs of activity, and reached the maximum planned dose of AV-203 monotherapy. The results were presented in a poster, entitled “First-in-human Phase 1 dose-escalation study of AV-203, a monoclonal antibody against ErbB3 in patients with metastatic or advanced solid tumors” at the Tumor Biology General Poster Session of the American Society of Clinical Oncology 2014 Annual Meeting, taking place May 30 - June 3, 2014, in Chicago.
News For AVEO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 13, 2015
07:04 EDTAVEOAveo Pharmaceuticals estimates Q4 cash, securities of $52M
Aveo Pharmaceuticals in conference presentation slides estimates its Q4 cash and securities at around $52M. Aveo said its streamlined operations by exiting a long term facilities lease and eliminating research functions. It cut its headcount from 60 to 20, which it expects to reduce annual compensation expenses by $6M. The company said it will reduce facilities requirements by up to 80% of its current space, including the elimination of lab and vivarium needs.
January 12, 2015
07:17 EDTAVEOJPMorgan to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use